MNK earnings call for the period ending December 31, 2019.
News & Analysis: Mallinckrodt
Investors are cheering the company's deal to settle opioid-related lawsuits.
Momentum from its CEO's comments earlier this week continues.
Investors appear to be optimistic about the drugmaker's impending Q3 update.
Investors continue to grapple with the uncertainty hanging over the company.
The company is reportedly considering bankruptcy to cope with its financial exposure in the opioid crisis.
Worries about opioid litigation and a recent patent lawsuit loss continue to weigh on the drugmaker.
The bad news keeps piling up.
Investors appear to have some confidence that the companies will settle their opioid lawsuits.
Positive clinical-trial results couldn't save the embroiled biotech.
The drugmaker's decision to suspend efforts to spin off its specialty generics business appears to be rattling investors.